Antigen binding molecules with increased fc receptor binding affinity and effector function
Abstract
The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Claims
exact text as granted — not AI-modified1 . An isolated polynucleotide comprising
a. a sequence selected from the group consisting of: SEQ ID NO:5, SEQ ID NO.: 6 and SEQ ID NO: 7; and b. a sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23; and c. sequence ID NO: 24.
2 - 259 . (canceled)Join the waitlist — get patent alerts
Track US2023212303A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.